

Product datasheet

AAV5 VP1, recombinant protein

Short overview

 Cat. No.
 640833

 Quantity
 10 μg

Concentration 100 µg/ml (1.19 µM)

Product description

Formulation Liquid, 6 M urea in PBS

Source Escherichia coli

Molecular Weight 82.6 kDa (calculated Mw from aa sequence)

Purity > 90% (determined by SDS PAGE)

Product description N-terminal His-tagged (MGSSHHHHHHHSSGLVPRGSH) recombinant AAV5 capsid protein VP1

UniprotID Q9YIJ1 (AAV5)

Purification Ni-NTA chromatography

Storage -80°C

Intended use Research use only
Application Dot blot, SDS PAGE, WB

Applications

Dot Blot 100 ng, depending on primary antibody and detection method


SDS PAGE 1 µ

Western Blot (WB) 5-20 ng, depending on primary antibody and detection method


Background

The AAV capsid consists of three capsid proteins, i.e. VP1, VP2 and VP3, which differ in their N-terminus and encapsulate the genomic ssDNA. In native virus particles, the three proteins form subunits with a ratio of 1:1:10 (VP1:VP2:VP3), in a total number of 60 subunits per capsid. The recombinant AAV5 VP1 protein in combination with recombinant AAV5 VP2 (Cat. No. 640834) and recombinant AAV5 VP3 (Cat. No. 640835) can be used to create a mixture with the precise molar ratio of 1:1:10 to compare the protein composition of the viral capsid in your sample by protein detection methods, e.g. western blot. All three recombinant AAV5 capsid proteins are available as set (Cat. No. 72005) or as individual proteins (Cat. No. 640833, 640834, 640835). Note: please find an example how to prepare western blot samples in the pipetting scheme below. Aliquots of the remaining samples can be stored at -80°C for reuse.


Product images



Pipetting scheme for western blot analysis using the AAV5 capsid proteins (Cat. No. 640833, 640834, 640835) in separate lanes. To analyze the molar ratio of 1:1:10, it is recommended to load VP1, VP2 and VP3 as described in the pipetting scheme above. Therefore, the indicated volumes of the proteins (concentration $100 \mu g/ml$) should be diluted with the appropriate amount of sample buffer and distilled water. $10 \mu l$ of each solution can be separately loaded onto the SDS PAGE and analyzed by Western blot using the B1 antibody (Cat. No. 690058, Cat. No. 61058-488, Cat. No. 61058-647).



Western blot analysis of recombinant AAV2 VP proteins (Cat. No. 72001), recombinant AAV5 VP proteins (Cat. No. 72005), recombinant AAV6 VP proteins (Cat. No. 72006), recombinant AAV8 VP proteins (Cat. No. 72008) and recombiant AAV9 VP proteins (Cat. No. 72009) with B1 antibody (Cat. No. 690058). Western blot analysis was performed on the precise molar ratio of 1:1:10 (13.5 ng VP1:11 ng VP2:100 ng VP3) combined in one lane. The PVDF membrane was blocked with 5% milk in PBST for 1 h at RT. The primary antibody anti-AAV VP1/VP2/VP3, B1 (Cat. No. 690058) was diluted in blocking buffer (antibody concentration 500 ng/ml) and incubated for 1 h at RT. The secondary antibody anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Western Blotting Substrate.



SDS PAGE analysis to evaluate the purity of the AAV5 VP1 (Cat. No. 640833). To perform SDS PAGE analysis, 1 μ g of protein was diluted in 10 μ l PBS and sample buffer and denatured at 95°C for 5 min. The sample was loaded onto a 4-20% gradient gel (40 min at 200 V). Afterwards, the gel was stained for 1 h at RT with Coomassie solution and destained with water. The purity of AAV5 VP is > 90%.